Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00407927 · ClinicalTrials.gov registry record · Phase 2
A Study of Epinastine Nasal Spray in Subjects With Seasonal Allergic Rhinitis
A Phase 2 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 2
- Development phase
- 571
- Enrollment target
NCT00407927: Completed Phase 2 study, sponsored by Merck Sharp & Dohme.
NCT00407927 is a Phase 2 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 571 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (329% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00407927, a Phase 2 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 571 participants
- Enrollment target
Study Summary
The purpose of this trial is to determine the safety, efficacy and tolerability of two doses of the study drug compared to placebo for the treatment of subjects with seasonal allergic rhinitis.
Interventions
- DRUG Epinastine Nasal Spray
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 571 participants |
| Start Date | 2006-12 |
| Est. Completion | 2007-03 |
| Phase | Phase 2 |
What the finished NCT00407927 record still lists
NCT00407927 is an interventional study that assigns participants to a tested intervention. The registered 571 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (329% higher).
The record links to 0 conditions, and to 1 intervention - of which Epinastine Nasal Spray is the first listed.
NCT00407927 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00407927 about?
NCT00407927 is a clinical study titled "A Study of Epinastine Nasal Spray in Subjects With Seasonal Allergic Rhinitis". The purpose of this trial is to determine the safety, efficacy and tolerability of two doses of the study drug compared to placebo for the treatment of subjects with seasonal allergic rhinitis.
What is the current status of trial NCT00407927?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 571 participants. The study started on 2006-12. Estimated completion is 2007-03.
What interventions are being tested in trial NCT00407927?
The interventions under investigation include: Epinastine Nasal Spray (DRUG).
Who is sponsoring clinical trial NCT00407927?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00407927's enrollment target sits among peer trials
571 59th of 2000 higher than 1,941 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04410796 · 571 participants · Phase 2
Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers
- NCT05131022 · 572 participants · Phase 1
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- NCT06346392 · 572 participants · Phase 3
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
- NCT06615050 · 572 participants · Phase 3
A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia